anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a remedy for tumor, effective to exterminate cancer cell by heating the monoclonal antibody bonded to the cancer cell, and having low side effects, by using a monoclonal antibody bonded with carbon which can be heated by the heat generated by high-frequency heating. CONSTITUTION:The objective antitumor agent is composed of a monoclonal antibody bonded with a carbon (e.g. graphite, amorphous carbon, etc.) which can be heated by high-frequency heating (preferably with radiation of 50Hz-30 MHz), and if necessary with a magnetic material (e.g. NaFeB alloy) and a carcinostatic agent. The induction current induced to the exterior part of the body by the electromagnetic induction effect of the high-frequency current generated by a high-frequency heater is directed to the cancer focus in the body, and the carbon bonded to the monoclonal antibody bonded specifically to the cancer cell of the focus is heated to 40-43 deg.C bu the high-frequency current to exterminate the cancer cell. Since the exterior surface of the body can be maintained at a low temperature, the heat-treatment can be continued for a long period to enable the complete extermination of the cancer cell.
PURPOSE: To obtain a cosmetic compsn. capable of increasing the elasticity of the skin and more particularly the elasticity of the horny layer by incorporating specific acyllactilate into the compsn. CONSTITUTION: The acyllactilate of the formula (RCO-(O-CHCH2 -CO)a O)b M (RCO is 4 to 16C acyl; M is H, paired ion of valance 1 or 2; (a) is 1 to 4; (b) is 1, 2); for example, sodium octanoyllactilate and a cosmetically permissible vehicle; for example, silicone water-in-oil type emulsion are mixed at 0.1 to 10 wt.% the former and 10 to 99.9 wt.% the latter. The elasticity of the skin and more particularly the elasticity of the external layer, i.e., horny layer, of the epidermis may be increased by using such acyllactilate. The topical application of the compsn. as a skin elasticity increasing agent is possible.
One hundred postmenopausal women, aged 50-75, who applied to the Physical Therapy and Rehabilitation outpatient clinic at Beylikdüzü State Hospital and have Dual-X-ray Absorptiometry (DXA) measurements taken within the last 6 months, including both osteoporotic and non-osteoporotic patients, will be included in the study. Sociodemographic data such as age, gender, height, weight, and BMI will be recorded. DXA results, including femoral neck and L1-L4 T-scores and BMD values, will be obtained. Patients will be asked about osteoporosis treatment, presence of fecal incontinence, constipation, and medication use. Stress urinary incontinence will be determined through a questionnaire, and its impact on quality of life will be assessed using the Incontinence Quality of Life Scale. In the second phase, sarcopenia will be evaluated according to the Asian Working Group for Sarcopenia (AWGS) criteria by assessing skeletal muscle mass (via bioelectrical impedance analysis), handgrip strength, and the 5-times sit-to-stand test.
Although the existing framework for classifying acute myocardial infarction (AMI) into STEMI and NSTEMI has been beneficial, it is now considered to be falling short in addressing the complexity of acute coronary syndromes. The study aims to scrutinize the current STEMI-NSTEMI paradigm and advocate for a more nuanced framework, termed as occlusion myocardial infarction (OMI) and non-occlusion myocardial infarction (NOMI), for a more accurate diagnosis and management of AMI. A comprehensive analysis of existing medical literature was conducted, with a focus on the limitations of the STEMI-NSTEMI model. The study also outlines a new diagnostic approach for patients presenting with chest pain in emergency settings. The traditional STEMI-NSTEMI model falls short in diagnostic precision and effective treatment, especially in identifying acute coronary artery occlusions. The OMI-NOMI framework offers a more anatomically and physiologically accurate model, backed by a wealth of clinical research and expert opinion. It underscores the need for quick ECG assessments and immediate reperfusion therapies for suspected OMI cases, aiming to improve patient outcomes. The OMI-NOMI framework offers a new avenue for future research and clinical application. It advocates for a more comprehensive understanding of the underlying mechanisms of acute coronary syndromes, leading to individualized treatment plans. This novel approach is expected to ignite further scholarly debate and research, particularly in the Brazilian cardiology sector, with the goal of enhancing diagnostic accuracy and treatment effectiveness in AMI patients.
The invention discloses synthetic SP series polypeptides and application thereof in treating cancer. The specific amino acid sequences of the synthetic SP series polypeptides are as shown in SEQ ID No. 1-11. The SP series polypeptides can be used for treating chronic myelogenous leukemia. The SP series polypeptides performs the function of treating leukemia by activating the activity of intracellular PP2A and conducting dephosphorylation on BCR/ABL, and also has a treatment effect on imatinib-resistant leukemia. The SP series polypeptides perform the function through SET/PP2A path, and have wide application in treating cancer.
A total of 20 subjects with Major Depressive Disorder (MDD), ages 18 to 65, will be consented and join this project at UCLA.

The project has two phases: a 12 week treatment phase and a 6 month follow-up phase. In the first phase, a double-blind one-way cross-over design will allow us to compare the clinical and physiologic responses to TNS at two frequencies of stimulation, "high" (\~120 Hz) and "low " (\~20 Hz). Subjects will be randomized to start a six week period at either high or low frequency stimulation (n=10 in each); both subjects and the staff who interact with them will be blinded to assignment, and a separate member of the team will program the device settings. At the six week point, the low frequency group subjects will be crossed over to high frequency, while the high frequency group will continue at high frequency. At the end of the 12 weeks, the TNS systems will be returned and the adjunctive treatment will end. All subjects will be followed for another six months with monthly telephone calls to monitor symptoms or changes in treatment that would signal a return of symptoms. The primary endpoint is the change in depression severity for the two groups at the week 6 visit.
A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
The invention discloses a preparation method of a hawthorn leaf extract, belongs to the field of extraction of hawthorn leaves and aims at solving the technical problems of high cost and low content of general flavone in a traditional preparation method of the hawthorn leaf extract. The preparation method comprises the following steps of: firstly, taking the hawthorn leaves, adding water, decocting and filtering; secondly, adding water in filter residue, decocting and filtering, combining the decoction obtained by two times, condensing and cooling; thirdly, adjusting the pH value to be 2-3, standing and combining supernate; fourthly, enabling the supernate to pass through a polyamide resin column and eluting with de-ionized water and ethanol solution; and fifthly, carrying out pressure-reduced recovery on ethanol, adjusting the pH value to be 6.0-6.5 and drying to obtain the hawthorn leaf extract. The content of the general flavone in the hawthorn leaf extract prepared by the invention is greater than 90 percent. The process steps of ethanol precipitation and cold storage are omitted. No organic solvent except the ethanol is adopted for treating. The preparation method is simpler and is more saving in preparation cost.
Patients should be informed that changes to insulin regimens must be made cautiously and only under medical supervision.

Patients should be informed about the potential side effects of insulin therapy, including lipodystrophy (and the need to rotate injection sites within the same body region), weight gain, allergic reactions, and hypoglycemia. Patients should be informed that the ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia should be advised to use caution when driving or operating machinery.

Accidental mix-ups between LANTUS and other insulins, particularly short-acting insulins, have been reported. To avoid medication errors between LANTUS and other insulins, patients should be instructed to always check the insulin label before each injection. 

LANTUS must only be used if the solution is clear and colorless with no particles visible. Patients must be advised that LANTUS must NOT be diluted or mixed with any other insulin or solution.

Patients should be advised not to share disposable or reusable insulin devices or needles with other patients, because doing so carries a risk for transmission of blood-borne pathogens.

Patients should be instructed on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia. Patients must be instructed on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. 

Patients with diabetes should be advised to inform their health care professional if they are pregnant or are contemplating pregnancy. 

Refer patients to the LANTUS "Patient Information" for additional information.
The exercises will be applied three times a week for four weeks. Each exercise is going to start with 10 repetitions and 1 set in the first session, and the exercises will be revised at the beginning of each week. Resistance will gradually be increased, and after four weeks, 3 sets of 10 repetitions will be targeted.
The invention provides a recombinant Sendai virus vector vaccine for expressing an immunodominant antigen of mycobacterium tuberculosis, which can be used as a therapeutic and prophylactic anti-tuberculosis vaccine. By intranasal immunization of the vaccine, a protective immune response against tubercle bacillus was successfully and effectively induced, and no pathological symptoms caused by immunization were observed. The antigen-specific cell immune response is successfully induced in a mouse model by taking the antigen as a preventive antitubercular vaccine through intranasal inoculation. Tubercle bacillus challenge protection experiments found that tubercle bacillus was significantly reduced in lungs and spleen of immunized mice compared to control animals, the mechanism of which was associated with a strong antigen-specific T cell immune response induced in the lungs, especially CD8+ T cell immune response. As a therapeutic vaccine, the anti-tuberculosis vaccine has the curative effect equivalent to that of Rifampicin (RFP), and the anti-tuberculosis effect can be obviously improved after the rifampicin and the RFP are combined. Therefore, the recombinant Sendai virus vector vaccine is one of the promising candidate vaccines against tuberculosis.
BACKGROUND: Conduction disturbances are a common complication of transcatheter aortic valve replacement (TAVR). Mobile Cardiac Telemetry (MCT) allows for continuous monitoring with near "real time" alerts and has allowed for timely detection of conduction abnormalities and pacemaker placement in small trials. A standardized, systematic approach utilizing MCT devices post TAVR has not been widely implemented, leading to variation in use across hospital systems.
OBJECTIVES: Our aim was to evaluate the utility of a standardized, systematic approach utilizing routine MCT to facilitate safe and earlier discharge by identifying conduction disturbances requiring permanent pacemaker (PPM) placement. We also sought to assess the occurrence of actionable arrhythmias in post-TAVR patients.
METHODS: Using guidance from the JACC Scientific Expert Panel, a protocol was implemented starting in December 2019 to guide PPM placement post-TAVR across our health system. All patients who underwent TAVR from December 2019 to June 2021 across four hospitals within Northwell Health, who did not receive or have a pre-existing PPM received an MCT device at discharge and were monitored for 30 days. Clinical and follow-up data were collected and compared to pre initiative patients.
RESULTS: During the initiative 693 patients were monitored with MCT upon discharge, 21 of whom required PPM placement. Eight of these patients had no conduction abnormality on initial or discharge ECG. 59 (8.6 %) patients were found to have new atrial fibrillation or flutter via MCT monitoring. There were no adverse events in the initiative group. Prior to the initiative, 1281 patients underwent TAVR over a one-year period. The initiative group had significantly shorter length of stay than pre-initiative patients (2.5 ± 4.5 vs 3.0 ± 3.8 days, p < 0.001) and lower overall PPM placement rate within 30 days post-TAVR (16 % vs 20.5 %, P = 0.0125).
CONCLUSIONS: In our study, implementation of a standardized, systematic approach utilizing MCT in post-TAVR patients was safe and allowed for timely detection of conduction abnormalities requiring pacemaker placement. This strategy also detected new atrial fibrillation and flutter. Reduction in post TAVR pacemaker rate and length of stay were also noted although this effect is multifactorial.
The invention provides a curable system and method of making a dental prosthesis. The method of making a dental prosthesis includes providing a one component denture base resin composition which is polymerizable by microwave energy. The one component denture base resin composition is injected into a mold enclosed by a flask having a body wall which is substantially transparent to the microwave energy. The curable system includes microwave energy sensitive initiators and polymerizables (meth)acrylate Monomers having molecular weights preferably between 400 and 20,000. The initiators are adapted to initiate polymerization of the polymerizable Monomers by application of microwave energy to the flask. The initiators are adapted to remain stable and not initiate polymerization of the Monomers for at least one year at 23° C. in the absence of microwave energy.
Participants with mechanical ventilation who have a bronchoalveolar lavage (BAL) planned as a part of routine practice will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
The invention relates to a suppository for treating cervical erosion and a preparation technology thereof. A hollow double-layer suppository as a base is filled with medical absorbent cotton to form a three-layer suppository. The preparation method of the three-layer suppository comprises the following steps of grinding curcuma rhizome and borneol to obtain fine powder, adding the fine powder into a matrix comprising semi-mixed fatty glyceride melt by heat, adding curcuma rhizome powder and a corresponding amount of basic fibroblast growth factor (bFGF) into a hot melt matrix comprising glycerin, gelatin and distilled water, orderly and respectively injecting the two drug-containing matrixes into middle and outer layers of a hollow double-layer suppository mold, rolling medical absorbent cotton to obtain a cylindrical roll, tying a drawing wire to the cylindrical roll, inserting a suppository core into the cylindrical roll, carrying out cooling and carrying out demolding. Through use of the double-layer suppository design, the outer and middle layers orderly produce effects. Curcuma rhizome and borneol in the fast-release layer have sterilization effects and provide a good physiological environment for slow-release layer action. Through the slow-release action mechanism, the middle layer maximizes the drug bFGF treatment effects and shortens a treatment course. The inner cotton core suppository design has cavity-cleaning effects.
Seventy five patients between 18-80 years of age who were hospitalized in intensive care unit were included in the study. The number of patients will be finalized by power analysis. whose written consent cannot be obtained and who undergo surgical tracheostomy for any reason will be excluded from the study. In addition, patients with active infection in the area of the procedure, bleeding diathesis and pathologies that interfere with the procedure in the ultrasonographic evaluation (thyroid diseases, etc.) will be excluded from the study. Patients will be divided into three groups as those using classical ventilation (group 1), HFJV (group 2) and classical laryngeal mask (group 3). Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
Heat-stabilized defatted rice bran (HDRB) is fermented with yeast to afford a food product having superior prebiotic for probiotic properties. Fermentation of HDRB with yeast yields a prebiotic composition that can promote the growth and/or activity of beneficial intestinal bacteria (probiotic) when consumed by an animal or human. The prebiotic and/or probiotic compositions can afford substances having desirable health effects when consumed. The yeast fermented, and the probiotic fermented extracts and residues will have several nutraceutical compounds including protein, phenolics, phytic acid, arabinose, bioactive isoflavones, dietary fibers and several others that will have health benefits. Inclusion of legumes during fermentation can synergistically enhance the bioactivities of HDRB. HDRB can be a source of growth medium for yeast/mold/microorganisms.
Subjects will be enrolled in the study for 26 weeks. During the first week, subject will come in to Mount Sinai for a study visit to complete a few questionnaires about sleep and mood, complete several memory tests and have an MRI of their brain. These study visits will take about 2 hours to complete. During this week, subject will also be asked to wear a wrist actigraph and light meter for 7 days. The actigraph is similar in size to a watch and is used to record their activity and rest patterns, and the light meter measures the amount of light they are exposed to during the day. After the completion of this week, subject will have a light treatment installed in their home that will be in place for 10 weeks. During the last week of the light treatment, subject will again come into Mount Sinai and repeat the questionnaires, memory tests and MRI, and wear the actigraph and light meter. After a 4-week break, subject will again come into Mount Sinai for a third study visit and complete the same questionnaires, memory tests, and MRI, and wear the actigraph and light meter. After this week, subject will have a different type of light treatment installed in their home and left in place for 10 weeks. During the last week of the light treatment, subject will come into Mount Sinai for the final study visit and complete the questionnaires, memory tests and MRI, and wear the actigraph and light meter for 7 days. There are no costs associated with participation, but subject will receive monetary compensation for each of the 4 study visits.
PURPOSE: An anti-cancer composition containing microRNA-125 nucleic acid molecule is provided to suppress infiltration and metastasis of cancer cells and angiogenesis. CONSTITUTION: An anti-cancer composition containing microRNA-125 nucleic acid molecule. The microRNA-125 is a microRNA-125a, microRNA-125b1 or microRNA-125b2 which is derived from human. The cancer is brain cancer, cervical cancer, breast cancer, bladder cancer, liver cancer, prostate cancer, and neuroblastoma. The microRNA-125 nucleic acid molecule is contained in a vector for expressing in a cell. The vector is lentivirus vector, retrovirus vector, adenovirus vector, herpersvirus vector, or avipoxvirus vector. The composition further comprises a pharmaceutically acceptable carrier. A composition for treating angiogenesis-relating disease which is induced under hypoxic condition contains the microRNA-125 nucleic acid molecule.
The usual initial antihypertensive oral dose of amlodipine besylate tablets is 5 mg once daily with a maximum dose of 10 mg once daily.

Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine besylate tablets to other antihypertensive therapy.

Adjust dosage according to each patient’s need. In general, titration should proceed over 7 to 14 days so that the physician can fully assess the patient’s response to each dose level. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently.

The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect [see Adverse Reactions (6)].

The recommended dose range for patients with coronary artery disease is 5 to 10 mg once daily. In clinical studies, the majority of patients required 10 mg [see Clinical Studies (14.4)].
Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.